168 related articles for article (PubMed ID: 20127030)
1. Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth.
Routhier A; Astuccio M; Lahey D; Monfredo N; Johnson A; Callahan W; Partington A; Fellows K; Ouellette L; Zhidro S; Goodrow C; Smith A; Sullivan K; Simone P; Le L; Vezuli B; Zohni M; West E; Gleason D; Bryan B
Oncol Rep; 2010 Mar; 23(3):861-7. PubMed ID: 20127030
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal administration of Y-27632, a specific rho-associated kinase inhibitor, for rat neoplastic meningitis.
Nakagawa H; Yoshioka K; Miyahara E; Fukushima Y; Tamura M; Itoh K
Mol Cancer Res; 2005 Aug; 3(8):425-33. PubMed ID: 16123138
[TBL] [Abstract][Full Text] [Related]
3. Organized migration of epithelial cells requires control of adhesion and protrusion through Rho kinase effectors.
Hopkins AM; Pineda AA; Winfree LM; Brown GT; Laukoetter MG; Nusrat A
Am J Physiol Gastrointest Liver Physiol; 2007 Mar; 292(3):G806-17. PubMed ID: 17138966
[TBL] [Abstract][Full Text] [Related]
4. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation.
Zohrabian VM; Forzani B; Chau Z; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2009 Jan; 29(1):119-23. PubMed ID: 19331140
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632.
Takamura M; Sakamoto M; Genda T; Ichida T; Asakura H; Hirohashi S
Hepatology; 2001 Mar; 33(3):577-81. PubMed ID: 11230737
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases.
Ishizaki T; Uehata M; Tamechika I; Keel J; Nonomura K; Maekawa M; Narumiya S
Mol Pharmacol; 2000 May; 57(5):976-83. PubMed ID: 10779382
[TBL] [Abstract][Full Text] [Related]
7. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma.
Nakajima M; Hayashi K; Egi Y; Katayama K; Amano Y; Uehata M; Ohtsuki M; Fujii A; Oshita K; Kataoka H; Chiba K; Goto N; Kondo T
Cancer Chemother Pharmacol; 2003 Oct; 52(4):319-24. PubMed ID: 12783205
[TBL] [Abstract][Full Text] [Related]
8. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells.
Lingor P; Tönges L; Pieper N; Bermel C; Barski E; Planchamp V; Bähr M
Brain; 2008 Jan; 131(Pt 1):250-63. PubMed ID: 18063589
[TBL] [Abstract][Full Text] [Related]
9. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells.
Somlyo AV; Bradshaw D; Ramos S; Murphy C; Myers CE; Somlyo AP
Biochem Biophys Res Commun; 2000 Mar; 269(3):652-9. PubMed ID: 10720471
[TBL] [Abstract][Full Text] [Related]
10. The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration.
Lepley D; Paik JH; Hla T; Ferrer F
Cancer Res; 2005 May; 65(9):3788-95. PubMed ID: 15867375
[TBL] [Abstract][Full Text] [Related]
11. E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells.
Hakuma N; Kinoshita I; Shimizu Y; Yamazaki K; Yoshida K; Nishimura M; Dosaka-Akita H
Cancer Res; 2005 Dec; 65(23):10776-82. PubMed ID: 16322223
[TBL] [Abstract][Full Text] [Related]
12. The Rho-kinase inhibitor Y-27632 inhibits cholestasis-induced platelet interactions in the hepatic microcirculation.
Laschke MW; Dold S; Menger MD; Jeppsson B; Thorlacius H
Microvasc Res; 2009 Jun; 78(1):95-9. PubMed ID: 19374910
[TBL] [Abstract][Full Text] [Related]
13. RhoA induces expression of inflammatory cytokine in adipocytes.
Nakayama Y; Komuro R; Yamamoto A; Miyata Y; Tanaka M; Matsuda M; Fukuhara A; Shimomura I
Biochem Biophys Res Commun; 2009 Feb; 379(2):288-92. PubMed ID: 19101507
[TBL] [Abstract][Full Text] [Related]
14. Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor.
Okumura N; Ueno M; Koizumi N; Sakamoto Y; Hirata K; Hamuro J; Kinoshita S
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3680-7. PubMed ID: 19387080
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of the effects of Y-27632.
Darenfed H; Dayanandan B; Zhang T; Hsieh SH; Fournier AE; Mandato CA
Cell Motil Cytoskeleton; 2007 Feb; 64(2):97-109. PubMed ID: 17009325
[TBL] [Abstract][Full Text] [Related]
16. Rho-associated kinase inhibitor Y-27632 promotes survival of cynomolgus monkey embryonic stem cells.
Takehara T; Teramura T; Onodera Y; Kakegawa R; Fukunaga N; Takenoshita M; Sagawa N; Fukuda K; Hosoi Y
Mol Hum Reprod; 2008 Nov; 14(11):627-34. PubMed ID: 18940855
[TBL] [Abstract][Full Text] [Related]
17. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility.
Honjo M; Tanihara H; Inatani M; Kido N; Sawamura T; Yue BY; Narumiya S; Honda Y
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):137-44. PubMed ID: 11133858
[TBL] [Abstract][Full Text] [Related]
18. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632.
Rao PV; Deng PF; Kumar J; Epstein DL
Invest Ophthalmol Vis Sci; 2001 Apr; 42(5):1029-37. PubMed ID: 11274082
[TBL] [Abstract][Full Text] [Related]
19. Adenosine-oligoarginine conjugate, a novel bisubstrate inhibitor, effectively dissociates the actin cytoskeleton.
Räägel H; Lust M; Uri A; Pooga M
FEBS J; 2008 Jul; 275(14):3608-24. PubMed ID: 18540886
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion.
Joshi B; Strugnell SS; Goetz JG; Kojic LD; Cox ME; Griffith OL; Chan SK; Jones SJ; Leung SP; Masoudi H; Leung S; Wiseman SM; Nabi IR
Cancer Res; 2008 Oct; 68(20):8210-20. PubMed ID: 18922892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
